Based on our comprehensive review of the current literature, we conclude that anti-PD-1/PD-L1- and/or anti-CTLA-4-based cancer treatment does not appear to increase vulnerability for SARS-CoV-2 infection per se. The gene discussed is CTLA4; the disease is cancer.